Literature DB >> 2262908

Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s.

S Imaoka1, K Enomoto, Y Oda, A Asada, M Fujimori, T Shimada, S Fujita, F P Guengerich, Y Funae.   

Abstract

The metabolism of lidocaine by human hepatic microsomes and purified human cytochrome P-450s, P-450NF (P450IIIA4), P-450MP (a P450IIC form) and P-450PA (P450IA2) was examined and their metabolism was compared with that by rat hepatic cytochrome P-450s. Human hepatic microsomes produced monoethylglycinexylidide (MEGX) and 3-hydroxylidocaine (3-OH-LID) from lidocaine. In a reconstituted system with dilauroylphosphatidylcholine, P-450NF efficiently produced MEGX. P-450PA was not efficient in lidocaine N-deethylation (formation of MEGX) but produced 3-OH-LID. P-450NF and P-450MP did not produce 3-OH-LID. Lidocaine N-deethylation activity of P-450NF was enhanced in a modified reconstituted system with a phospholipid mixture and sodium cholate. P-450NF appears to be an ortholog to rat P450 PB-1 (P450IIIA2). Anti-P450 PB-1 antibody cross-reacted with P-450NF and efficiently inhibited lidocaine N-deethylation in human hepatic microsomes. The correlation of lidocaine N-deethylation activity with the concentration of P-450NF determined immunochemically with anti-P450 PB-1 antibody was good (r = 0.81). In addition, correlation between P-450NF content estimated with anti-P450 PB-1 and anti-P-450NF preparations was good (r = 0.96). These results suggest that rat P450 PB-1 and human P-450NF have closely related properties and P-450NF is the major enzyme involved in lidocaine N-deethylation in human hepatic microsomes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2262908

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

Review 1.  A survey of the literature (1995-1999) on the kinetics of drugs in camels (Camelus dromedarius).

Authors:  A A Alquarawi; B H Ali
Journal:  Vet Res Commun       Date:  2000-05       Impact factor: 2.459

2.  The effects of gender and menopause on serum lidocaine levels in smokers.

Authors:  Sermin Oztekin; Omur Mavioglu; Zahide Elar; Hulya Guven; Sule Kalkan; Tugba Gurpinar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

3.  Three-dimensional co-culture of hepatocytes and stellate cells.

Authors:  Susan Fugett Abu-Absi; Linda K Hansen; Wei-Shou Hu
Journal:  Cytotechnology       Date:  2004-07       Impact factor: 2.058

4.  The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans.

Authors:  C Reichel; T Skodra; A Nacke; U Spengler; T Sauerbruch
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

5.  Lidocaïne test for easier and less time consuming assessment of liver function in several hepatic injury models.

Authors:  Dorra Ben Said; Ridha Ben Ali; Henda Ferchichi; Issam Salouage; Lobna Ouanes; Emna Gaïes; Sameh Trabelsi; Emna Kooli; Nadia Kourda; Jaouida Abdelmoula; Mohamed Lakhal; Anis Klouz
Journal:  Hepatol Int       Date:  2011-03-23       Impact factor: 6.047

6.  Extended liver-specific functions of porcine hepatocyte spheroids entrapped in collagen gel.

Authors:  A Lazar; H J Mann; R P Remmel; R A Shatford; F B Cerra; W S Hu
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-05       Impact factor: 2.416

Review 7.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

8.  Stress-induced lidocaine modification in serum and tissues.

Authors:  T Saranteas; C Tesseromatis; A Potamianou; C Mourouzis; D Varonos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

Review 9.  Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.

Authors:  G R Jang; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1997-12

10.  Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.

Authors:  Marika T Granfors; Janne T Backman; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.